Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

Core Insights - Evoke Pharma, Inc. is set to present an abstract at the 2024 Digestive Disease Week Conference, focusing on the benefits of GIMOTI (metoclopramide) nasal spray for enhancing gastroparesis care in women [1][2] Company Overview - Evoke Pharma is a specialty pharmaceutical company dedicated to developing treatments for gastrointestinal diseases, particularly through its product GIMOTI, which is a nasal spray formulation of metoclopramide [10] - GIMOTI is specifically indicated for adults suffering from acute and recurrent diabetic gastroparesis, a condition that affects the stomach's ability to empty [11] Conference Details - The presentation titled "Transforming Diabetic Gastroparesis Care in Women: Insights from Nasal Metoclopramide Usage" will be led by Dr. David C. Kunkel at the DDW 2024, scheduled for May 20, 2024 [3] - The conference will take place from May 18-21, 2024, in Washington D.C., featuring over 4,400 abstracts and numerous lectures on advancements in gastrointestinal research [4] Product Benefits - The company emphasizes the positive therapeutic impact of GIMOTI on women, who are the demographic most affected by gastroparesis, highlighting reduced physician visits and hospitalizations compared to oral metoclopramide [2] - GIMOTI is the only FDA-approved drug in the U.S. for treating gastroparesis, previously only available in oral and injectable forms [11]